• Profile
Close

Safety, tolerability, and pharmacodynamics of ABT-122, a TNF- and IL-17–targeted dual variable domain immunoglobulin, in patients with RA

Arthritis & Rheumatism Sep 25, 2017

Fleischmann RM, et al. - A two phase 1, placebo-controlled, multiple-dose studies are done to report the pooled safety, tolerability, and exploratory pharmacodynamics of ABT-122 in patients with primarily inactive rheumatoid arthritis (RA). The outcome of this phase 1 study recommends that dual neutralization with ABT-122 has a profile acceptable for further investigation of therapeutic potential in TNF- and IL-17A–driven immune-mediated inflammatory diseases.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay